GLP-1 Medications Show Potential in Treating Depression and Addiction

GLP-1 medications, commonly prescribed for overweight, obesity, and type 2 diabetes, are gaining attention for their potential role in treating certain psychiatric conditions. Research indicates that these drugs may help improve symptoms of depression and substance use disorders.

People with diabetes or obesity face a higher risk of developing depression, anxiety, and suicidal tendencies, according to Taipale (2026). Evidence suggests that GLP-1 drugs can alleviate these co-occurring conditions in some patients.

How GLP-1 Functions in the Body and Brain

GLP-1 is a hormone released by the intestinal tract in response to food intake. It promotes insulin secretion from the pancreas, delays gastric emptying, and induces feelings of fullness. Additionally, GLP-1 is produced in the brain, where it influences nerve function, energy balance, appetite regulation, and the brain's reward mechanisms related to food and drug intake (Angarita, 2021).

Furthermore, GLP-1 reduces inflammation and oxidative stress, factors linked to the development of depression and anxiety (Gunturu, 2024). Several studies have documented improvements in depressive symptoms following GLP-1 treatment (Gunturu, 2024). For instance, Chen (2024) reported a significant decrease in depression scores among subjects receiving GLP-1 compared to those given a placebo.

Besides mood improvements, GLP-1 exhibits neuroprotective properties (Cooper, 2023). However, a study involving obese participants did not find GLP-1 effective in preventing depression, anxiety, or suicidal behavior, though it did not assess symptom improvement in already depressed subjects (Kornelius, 2024).

Initial FDA surveillance raised concerns about increased suicidal ideation and behavior among GLP-1 users, but subsequent data led the FDA to conclude that these drugs do not elevate such risks (Drug Safety Communication, 2026). Supporting this, Pierret (2025) found no association between GLP-1 use and psychiatric adverse events or worsening depression symptoms.

GLP-1 and Substance Use Disorders

Research supports GLP-1 medications as a treatment option for alcohol and other substance use disorders (Farokhnia, 2026). These drugs inhibit dopamine release in the brain's reward centers, which is relevant to addiction mechanisms (Laurindo, 2022).

Alcohol use disorder has been the most extensively studied addiction in relation to GLP-1 treatment. Hendershot (2025) found that low-dose semaglutide reduced alcohol consumption, daily drinks, and weekly cravings. Similarly, Klausen (2022) reported significant decreases in heavy drinking days and total alcohol intake among obese patients treated with a GLP-1 drug, noting that benefits were primarily observed in overweight or obese individuals.

Overall, overweight, obese, or diabetic subjects tend to respond better to GLP-1 therapy for substance use disorders than normal-weight individuals (Marquez-Meneses, 2025). Beyond alcohol, studies have examined GLP-1 effects on psychostimulants, opioids, and nicotine addictions (Bruns, 2024).

Nicotine dependence remains a significant public health challenge. GLP-1 has been shown to reduce voluntary nicotine use and prevent weight gain associated with withdrawal (Herman, 2024). Additionally, GLP-1 may improve cognitive deficits and depressive or anxiety-like behaviors that contribute to relapse during smoking cessation (Herman, 2024).

Considerations for Eating Disorders and Weight Management

Binge eating disorder (BED) is the most prevalent specific eating disorder and is often linked with ADHD, mood disorders, anxiety, substance use disorders, and obesity (Himmerich, 2024). While the role of GLP-1 in treating BED is not fully established, research indicates these medications can reduce binge eating in overweight or obese individuals (Himmerich, 2024). Neuropsychiatric effects of GLP-1 may also lower the risk of BED (Choudhury, 2026).

However, misuse of GLP-1 drugs to maintain eating disorders such as anorexia nervosa, bulimia nervosa, or BED through rapid weight loss is reported and considered unsafe (Peiper, 2026). GLP-1 medications should not be used for eating disorders outside of research settings.

Weight gain is a common side effect of many antidepressants and antipsychotics, leading some patients to discontinue their medications. Pharmacologic strategies to manage this include adding metformin or GLP-1 drugs (Solmi, 2024; Mouawad, 2025). In a study involving patients with schizophrenia, prediabetes, and obesity, GLP-1 treatment over 30 weeks was safe, reduced blood glucose and weight by an average of 20.3 pounds, and improved physical quality of life without worsening mental health (Ganeshalingam, 2025).

Research on GLP-1 and Anxiety Disorders

Human studies on GLP-1 for anxiety management are limited. Animal research consistently shows reduced anxiety-like behavior and improved stress resilience markers. Clinical studies in humans have yielded mixed but suggestive evidence of reduced anxiety incidence and lower suicidal ideation risk (Yi, 2026).

GLP-1 medications continue to be investigated as potential treatments for various mental health conditions. Among these, depression and substance use disorders have the most supporting data. Larger and more comprehensive studies are necessary to determine optimal dosing and clinical guidelines for psychiatric applications of GLP-1 drugs.